Why the study?
Estradiol is implicated in the higher arrhythmia risk of women with long-QT syndrome compared to men, but underlying mechanisms and the impact of long-QT mutations remain poorly understood.
Does 17β-estradiol inhibit Kv7.1/KCNE1 channels and how do LQTS mutations affect this response in Xenopus oocytes?
Does 17β-estradiol inhibit Kv7.1/KCNE1 channels and how do LQTS mutations affect this response in Xenopus oocytes?
Answers are grounded in this paper and cite their sources.
17β-estradiol inhibits the Kv7.1/KCNE1 channel in a mutation-dependent manner, providing a mechanistic basis for the higher arrhythmia risk observed in women with specific long-QT syndrome mutations.
Estradiol (17[Formula: see text]-E2) is implicated in higher arrhythmia risk of women with congenital or acquired long-QT syndrome (LQTS) compared to men. However, the underlying mechanisms remain poorly understood, and little is known about the impact of LQTS-associated mutations. We show that 17[Formula: see text]-E2 inhibits the human cardiac Kv7.1/KCNE1 channel expressed in Xenopus oocytes. We find that the 17[Formula: see text]-E2 effect depends on the Kv7.1 to KCNE1 stoichiometry, and we reveal a critical function of the KCNE1 carboxyl terminus for the effect. LQTS-associated mutations in the KCNE1 carboxyl terminus show a range of responses to 17[Formula: see text]-E2, from a wild-type like response to impaired or abolished response. Together, this study increases our understanding of the mechanistic basis for 17[Formula: see text]-E2 inhibition of Kv7.1/KCNE1 and demonstrates mutation-dependent responses to 17[Formula: see text]-E2. These findings suggest that the 17[Formula: see text]-E2 effect on Kv7.1/KCNE1 might contribute to the higher arrhythmia risk of women, particularly in carriers with specific LQTS-associated mutations.
No takes yet. Share an insight, caveat, or question.
Erlandsdotter et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: